Skip to Content
Merck
CN

B-044

Buprenorphine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C29H41NO4
CAS Number:
Molecular Weight:
467.64
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

certified reference material

Quality Level

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland

concentration

1.0 mg/mL in methanol

technique(s)

liquid chromatography (LC): suitable, gas chromatography (GC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

InChI key

RMRJXGBAOAMLHD-IHFGGWKQSA-N

General description

A Certified Spiking Solution® suitable for GC/MS or LC/MS applications in pain prescription monitoring, forensic testing, or clinical toxicology.

Buprenorphine is a semi-synthetic opioid that shows partial agonistic activity towards the μ-opioid receptor and antagonistic activity towards the kappa opioid receptor. And even though it is similar to morphine, it is more potent than morphine. The drug is sold under numerous trade names such as Suboxone®, Subutex®, and Temgesic.

Application

The certified reference solution (CRM) in solution can also be used as follows:
  • Multi-residue analysis of buprenorphine, norbuprenorphine, and naloxone in the fingernails and urine samples of previous heroin users under an opioid substitution therapy by solid-liquid or solid-phase extraction combined with liquid chromatography-mass spectrometry (LC-MS) for analysis
  • Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) based separation and determination of naloxone, buprenorphine, and norbuprenorphine in human plasma samples following their single-step liquid-liquid extraction (LLE)
  • Development of nanocomposite rhodium nanoparticles-mesoporous carbon (RhNPs-MC) for their deposition on glassy carbon electrode (GCE) to compose an electrochemical sensor for the measurement of morphine and buprenorphine in pharmaceutical formulations and human serum samples using differential pulse voltammetry (DPV)
  • Study of human blood plasma samples for the quantitative analysis of buprenorphine and naloxone by liquid chromatography (LC) coupled to high-resolution time-of-flight mass spectrometry (HR-Q-TOF-MS)
  • Simultaneous determination of buprenorphine, norbuprenorphine, and their glucuronides from human urine samples by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS)

Features and Benefits

  • Fully characterized under ISO/IEC 17025 and ISO 17034 accreditation
  • Accompanied with a comprehensive Certificate of Analysis (CoA) with data on stability, homogeneity, accuracy of concentration, uncertainty, and traceability
  • Rigorously tested through real-time stability studies to ensure accuracy and shelf life
  • Gravimetrically prepared using qualified precision balances to ensure minimal uncertainty
  • Flame sealed under argon into ampoules for long-term shelf life
  • Offered in a convenient, DEA-exempt format to improve laboratory efficiency

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited
German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.


Still not finding the right product?

Explore all of our products under Buprenorphine solution


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

监管及禁止进口产品

This item has



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Protocols

为了使用β-葡糖醛酸酶优化水解,必须对每种待分析的葡糖苷酸代谢物进行某些因素的评估,例如孵育时间、温度、水解pH、酶源和酶浓度。

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Articles

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.


O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
P M J Clement et al.
Acta clinica Belgica, 68(2), 87-91 (2013-08-24)
Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented
E J Love et al.
The Veterinary record, 172(24), 635-635 (2013-06-06)
Buprenorphine has recently obtained UK Marketing Authorisation for horses. The analgesic effects are long lasting, and have considerable potential for postoperative pain relief. This observer blinded, randomised study aimed to evaluate postsurgical analgesia in ponies premedicated with buprenorphine prior to



Global Trade Item Number

SKUGTIN
B-044-1ML04061833419199